F-STAR THERAPEUTICS
F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-starโs Modular Antibody Technology:tm: enables rapid discovery and development... of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.
F-STAR THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2006-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.f-star.com
Total Employee:
51+
Status:
Active
Contact:
+43 (0)-72055-4215
Email Addresses:
[email protected]
Total Funding:
137.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins Nginx Sitelinks Search Box
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2020-11-20 | Spring Bank Pharmaceuticals | Spring Bank Pharmaceuticals acquired by F-Star Therapeutics | 30 M USD |
Investors List
Aescap Venture
Aescap Venture investment in Post-IPO Equity - F-Star Therapeutics
Atlas Venture
Atlas Venture investment in Post-IPO Equity - F-Star Therapeutics
SR One
SR One investment in Post-IPO Equity - F-Star Therapeutics
M Ventures
M Ventures investment in Post-IPO Equity - F-Star Therapeutics
M Ventures
M Ventures investment in Series A - F-Star Therapeutics
Aescap Venture
Aescap Venture investment in Series A - F-Star Therapeutics
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series A - F-Star Therapeutics
SR One
SR One investment in Series A - F-Star Therapeutics
Atlas Venture
Atlas Venture investment in Series A - F-Star Therapeutics
TVM Capital
TVM Capital investment in Series A - F-Star Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-03-01 | F-star Therapeutics Appoints James Sandy as Chief Development Officer |
Official Site Inspections
http://www.f-star.com Semrush global rank: 4.61 M Semrush visits lastest month: 2.2 K
- Host name: 160.89.214.35.bc.googleusercontent.com
- IP address: 35.214.89.160
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043